Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Healthequity (HQY) Research & Development (2016 - 2026)

Healthequity has reported Research & Development over the past 14 years, most recently at $70.4 million for Q1 2026.

  • For Q1 2026, Research & Development rose 8.82% year-over-year to $70.4 million; the TTM value through Jan 2026 reached $262.5 million, up 9.6%, while the annual FY2026 figure was $262.5 million, 9.6% up from the prior year.
  • Research & Development for Q1 2026 was $70.4 million at Healthequity, up from $65.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $70.4 million in Q1 2026 and troughed at $45.2 million in Q2 2022.
  • A 5-year average of $56.5 million and a median of $55.6 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 42.11% in 2022 and later rose 4.77% in 2024.
  • Year by year, Research & Development stood at $48.9 million in 2022, then grew by 13.75% to $55.6 million in 2023, then rose by 8.23% to $60.2 million in 2024, then grew by 9.52% to $65.9 million in 2025, then rose by 6.73% to $70.4 million in 2026.
  • Business Quant data shows Research & Development for HQY at $70.4 million in Q1 2026, $65.9 million in Q4 2025, and $64.8 million in Q3 2025.